Last updated: September 6, 2026
Xibrom, the former branded bromfenac ophthalmic solution 0.09%, has no meaningful current branded market in the United States. Its commercial trajectory moved from ISTA Pharmaceuticals’ pre- and post-cataract-surgery ophthalmic franchise to generic erosion, product discontinuation, and migration toward newer bromfenac products, particularly Prolensa. Bausch + Lomb acquired ISTA in 2012, but public filings did not disclose standalone Xibrom revenue. Current value in the bromfenac market is concentrated in generic ophthalmic products and successor branded formulations rather than Xibrom itself.
What is Xibrom and what was it approved to treat?
Xibrom is the brand name for bromfenac ophthalmic solution 0.09%, a topical nonsteroidal anti-inflammatory drug, or NSAID. The product was used to treat ocular inflammation and pain after cataract surgery.
The U.S. Food and Drug Administration approved Xibrom under New Drug Application 21-664. The original labeling directed patients to administer one drop in the affected eye twice daily, beginning the day before cataract surgery and continuing for 14 days after surgery. Bromfenac inhibits cyclooxygenase-mediated prostaglandin production, reducing postoperative inflammation and pain.
| Attribute |
Xibrom |
| Active ingredient |
Bromfenac sodium sesquihydrate |
| Strength |
0.09% ophthalmic solution |
| Dosage form |
Topical ophthalmic solution |
| Initial sponsor |
ISTA Pharmaceuticals |
| FDA application |
NDA 21-664 |
| Primary use |
Postoperative ocular inflammation and pain |
| Original dosing |
Twice daily |
| Therapeutic class |
Ophthalmic NSAID |
| Current U.S. commercial status |
Brand product discontinued |
| Main substitutes |
Generic bromfenac 0.09%, Prolensa 0.07%, other ophthalmic NSAIDs |
FDA records identify Xibrom as discontinued for commercial reasons rather than withdrawn because of safety or efficacy concerns.[1]
When did Xibrom lose exclusivity?
Xibrom’s commercial exclusivity declined after the emergence of generic bromfenac ophthalmic products and competing once-daily formulations. The product’s position weakened further when ISTA and later Bausch + Lomb shifted commercial attention to Bromday and Prolensa.
Xibrom had several forms of protection:
- FDA regulatory exclusivity associated with the original NDA.
- Patent protection covering bromfenac ophthalmic formulations and related methods.
- Brand and formulation differentiation based on dosing frequency and postoperative use.
- Commercial protection from physician familiarity and surgical-center purchasing relationships.
The initial regulatory exclusivity period has expired. Xibrom no longer has an active commercial exclusivity position comparable to a protected branded launch product. Generic bromfenac products compete directly with the former Xibrom formulation.
What were the key Xibrom patent expiration dates?
A definitive patent-expiration analysis requires the historical Orange Book patent listings associated with NDA 21-664 and any terminal-disclaimer or patent-term-adjustment calculations. Public commercial evidence establishes that the relevant Xibrom protection has expired or is no longer blocking generic market participation.
The key business conclusion is that no active Xibrom patent estate currently prevents generic bromfenac 0.09% competition in the United States. Formulation patents associated with bromfenac ophthalmic products may have had different expiration dates from the original active-ingredient or development patents, but they no longer support a current Xibrom monopoly.
What is the Orange Book status of Xibrom?
Xibrom is not a current growth product in the Orange Book market. The relevant NDA remains historically important because it established the approved 0.09% bromfenac ophthalmic product, but the branded product has been discontinued.
The FDA’s discontinued-drug records distinguish commercial discontinuation from withdrawal for safety or effectiveness. That distinction matters for generic applicants because a product discontinued for commercial reasons can remain a reference point for abbreviated approval pathways, subject to FDA determinations and applicable regulatory requirements.[1]
The Orange Book implications are:
- Xibrom is not a current branded product with meaningful commercial exclusivity.
- Generic bromfenac applicants can compete against the established reference product.
- Historical patent listings do not create a current branded pricing barrier.
- Prolensa is a separate product with a different strength and formulation profile.
How did Xibrom compare with Bromday and Prolensa?
Xibrom, Bromday, and Prolensa were successive bromfenac products associated with ISTA and later Bausch + Lomb.
| Product |
Bromfenac strength |
Dosing profile |
Commercial role |
| Xibrom |
0.09% |
Twice daily |
Original branded product |
| Bromday |
0.09% |
Once daily |
Reformulated or repositioned successor |
| Prolensa |
0.07% |
Once daily |
Later branded product with differentiated formulation and dosing |
Bromday’s once-daily regimen reduced administration burden compared with Xibrom. Prolensa used a lower bromfenac concentration and a formulation positioned for once-daily postoperative treatment. These products allowed the sponsor to defend the bromfenac franchise through product migration rather than relying solely on the original Xibrom brand.
The competitive set also includes ketorolac ophthalmic products, nepafenac products such as Nevanac, and generic ophthalmic NSAIDs. Cataract surgeons select among these products based on dosing, formulary status, price, perceived tolerability, reimbursement, and relationships with surgical centers.
What company owned Xibrom and how did licensing affect the product?
ISTA Pharmaceuticals developed and commercialized Xibrom. Bausch + Lomb acquired ISTA in 2012 for approximately $500 million, expanding Bausch + Lomb’s ophthalmic pharmaceutical portfolio.[2]
The transaction gave Bausch + Lomb access to ISTA’s ophthalmic products, commercial infrastructure, and development programs. Xibrom itself was no longer the primary growth asset by the time of the acquisition. The strategic value was the broader ophthalmic franchise, including branded postoperative products and pipeline assets.
Public disclosures do not identify a major third-party licensing transaction that independently drove Xibrom’s economics. The principal ownership event was the ISTA acquisition by Bausch + Lomb.
What was Xibrom’s financial trajectory?
Standalone Xibrom revenue was not separately reported in the public financial statements reviewed for ISTA or Bausch + Lomb. Reported figures generally grouped Xibrom with other ophthalmic products. As a result, product-level peak sales, gross margin, and cumulative revenue cannot be stated as audited figures.
The financial trajectory can be divided into four phases.
Launch and adoption
Xibrom entered a growing cataract-surgery market with a convenient topical NSAID formulation. Its commercial value came from postoperative prescribing volume rather than chronic use. The product benefited from the large number of cataract procedures performed annually in the United States and from routine use of anti-inflammatory therapy after surgery.
Franchise expansion
ISTA expanded the bromfenac franchise through once-daily positioning and additional products. This reduced reliance on Xibrom but also shortened the period during which the original brand was the principal revenue generator.
ISTA’s public filings reported company-level product revenue rather than a distinct Xibrom line item. The company’s ophthalmic commercial base included Xibrom, Vitrase, Azasite, Bromday, and other products.[3]
Acquisition and portfolio integration
Bausch + Lomb acquired ISTA in 2012. The transaction shifted Xibrom from an independent biotechnology-company asset to a product within a larger ophthalmology portfolio. Bausch + Lomb had greater commercial scale but also had less need to preserve Xibrom as a standalone brand after newer bromfenac formulations became available.
Generic erosion and discontinuation
Generic bromfenac 0.09% reduced the price premium available to Xibrom. Cataract-surgery products are especially exposed to substitution because treatment duration is short, physicians can switch products relatively easily, and payers and surgical centers exert purchasing pressure.
The product’s revenue trajectory therefore became structurally negative even if prescription demand for topical bromfenac remained strong. The market transitioned from a branded-product model to a volume-driven generic model.
Which companies challenged Xibrom with generic products?
Generic competition came from ophthalmic manufacturers operating through abbreviated new drug applications. The relevant competitive group has included companies such as Apotex and other generic ophthalmic manufacturers, depending on product availability and market period.
The principal challenge was not a biosimilar challenge. Xibrom is a small-molecule ophthalmic drug, so the relevant pathway is the ANDA process rather than the biosimilar pathway under the Public Health Service Act.
Generic entrants compete on:
- Wholesale acquisition price.
- Pharmacy and payer coverage.
- Supply reliability.
- Dropper design and packaging.
- Hospital and ambulatory surgery center contracts.
- Ability to substitute for the reference product.
What generic entry risks affected Xibrom?
The generic entry risk was high because Xibrom had several characteristics associated with rapid erosion:
- It was a small-molecule drug.
- The treatment course was short.
- The active ingredient was chemically defined.
- Generic substitution was commercially practical.
- The principal use was a high-volume surgical procedure.
- Competing ophthalmic NSAIDs were already available.
- The product had no durable biologic manufacturing barrier.
Paragraph IV litigation may have occurred around individual generic applications and historical patent listings, but Xibrom’s current commercial status does not depend on unresolved litigation. No active, material Xibrom patent dispute is necessary to explain the product’s loss of market position.
Does Xibrom face biosimilar risk?
No. Xibrom does not face biosimilar risk because bromfenac is a small-molecule active ingredient, not a biologic. The applicable competition is generic ophthalmic bromfenac submitted through ANDAs.
The relevant regulatory risks are generic approval, substitution, manufacturing quality, ophthalmic sterility, device performance, and supply continuity.
What manufacturing and intellectual-property barriers remain?
The main manufacturing barrier is sterile ophthalmic production. Manufacturers must control sterility, particulate matter, extractables, leachables, container closure integrity, and preservative performance where applicable. These requirements create operational barriers but do not provide Xibrom with durable exclusivity.
The intellectual-property barriers are also limited. Historical formulation and manufacturing patents may have protected particular compositions or processes, but generic products can enter after relevant claims expire, are successfully challenged, or are avoided through alternative formulations.
Prolensa may retain more commercial differentiation than Xibrom because it is associated with a separate strength and formulation. That distinction does not restore exclusivity to Xibrom 0.09%.
What is the current market outlook for bromfenac ophthalmic products?
The bromfenac ophthalmic market remains tied to cataract surgery volumes, but the economic mix has changed.
| Market driver |
Effect on Xibrom |
Effect on generic bromfenac |
| Growth in cataract procedures |
Positive demand effect |
Positive demand effect |
| Generic substitution |
Negative |
Positive volume opportunity |
| Once-daily dosing |
Weakens Xibrom differentiation |
Supports branded or differentiated products |
| Payer cost controls |
Negative |
Positive |
| Surgical-center purchasing |
Negative for legacy brand |
Favors low-cost suppliers |
| Product shortages |
Can temporarily shift share |
Creates intermittent pricing opportunity |
| Competing NSAIDs |
Limits pricing power |
Expands substitution options |
The market’s volume outlook is more favorable than its branded-price outlook. A manufacturer can generate revenue from generic bromfenac through scale, supply reliability, and contracting, but Xibrom no longer has a credible path to substantial branded growth.
What is the investment and licensing significance of Xibrom?
Xibrom has limited standalone licensing value. Its strategic relevance is historical and franchise-based rather than asset-based.
A buyer or licensee would not normally acquire Xibrom for protected branded revenue. The potential value would instead arise from:
- Access to ophthalmic commercial channels.
- Manufacturing or distribution scale.
- A broader portfolio transaction.
- Supply rights for generic bromfenac.
- Combination with other postoperative ophthalmic products.
The absence of separately disclosed Xibrom revenue prevents a reliable product-level valuation. Bausch + Lomb’s acquisition of ISTA should be analyzed as a portfolio transaction, not as a disclosed valuation of Xibrom alone.
Key Takeaways
- Xibrom is bromfenac ophthalmic solution 0.09%, originally commercialized by ISTA Pharmaceuticals.
- FDA approval covered postoperative ocular inflammation and pain after cataract surgery.
- The product was commercially displaced by generic bromfenac and successor branded products.
- Bausch + Lomb acquired ISTA in 2012 for approximately $500 million.
- Xibrom was discontinued for commercial reasons, not because of an identified safety or efficacy withdrawal.
- Public filings did not disclose standalone Xibrom revenue.
- The product has no meaningful current U.S. branded exclusivity.
- Competition is generic, not biosimilar.
- Prolensa and other ophthalmic NSAIDs are more relevant current branded comparators.
- The bromfenac market can retain procedure-driven volume while losing branded pricing power.
FAQs
Is Xibrom still available in the United States?
The original Xibrom brand is discontinued in the United States. Generic bromfenac ophthalmic products may remain available, subject to manufacturer supply and market status.
What drug replaced Xibrom?
Bromday and later Prolensa were the principal branded successor products associated with the ISTA and Bausch + Lomb ophthalmic franchise. Generic bromfenac 0.09% is the closest commercial substitute for Xibrom.
Is generic bromfenac the same as Xibrom?
Generic bromfenac 0.09% is intended to provide the same active ingredient and strength as Xibrom, but inactive ingredients, packaging, device characteristics, and labeling details may differ by manufacturer.
Did Bausch + Lomb buy Xibrom?
Bausch + Lomb did not acquire Xibrom as an isolated asset. It acquired ISTA Pharmaceuticals in 2012, obtaining ISTA’s ophthalmic portfolio, which included Xibrom-related commercial products and bromfenac franchise assets.
Can Xibrom generate future licensing revenue?
Material future licensing revenue from the discontinued Xibrom brand is unlikely. Any remaining commercial value would be tied to generic supply, portfolio distribution, manufacturing rights, or related ophthalmic products rather than the original Xibrom brand.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and discontinued drug product records for Xibrom, NDA 21-664.
- Bausch & Lomb. (2012). Bausch + Lomb completes acquisition of ISTA Pharmaceuticals.
- ISTA Pharmaceuticals, Inc. (2012). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2011. U.S. Securities and Exchange Commission.
- U.S. Food and Drug Administration. (2005). Xibrom bromfenac ophthalmic solution 0.09% prescribing information.
- U.S. Food and Drug Administration. (2013). Prolensa bromfenac ophthalmic solution 0.07% prescribing information.
